Reuters logo
BRIEF-Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​
November 9, 2017 / 7:30 AM / a month ago

BRIEF-Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​

Nov 9 (Reuters) - HIKMA PHARMACEUTICALS PLC:

* ‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​

* FOR FULL YEAR ‍CONTINUE TO EXPECT GLOBAL INJECTABLES REVENUE TO BE AROUND $775 MILLION, WITH A VERY STRONG CORE OPERATING MARGIN OF AROUND 39%​

* ‍EXPECT GENERICS REVENUE TO BE AROUND $600 MILLION FOR FULL YEAR AND CORE OPERATING MARGIN TO BE IN LOW SINGLE-DIGITS​

* ‍REITERATING EXPECTATION FOR BRANDED REVENUE GROWTH IN MID-SINGLE DIGITS IN CONSTANT CURRENCY IN 2017​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below